Form 4 for NAGE Niagen Bioscience, Inc.
Accepted 2024-11-25 00:00:00 ET · period of report 2024-11-22 · accession 0001628280-24-049079 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-25 | 2024-11-22 | NAGE | Pamir Ozan | CFO | P - Purchase | $7.36 | +2,907 | 2,907 | New | +$21.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-22 | P | A | 2,907.20 | $7.36 | 2,907.20 | D | — | — | (F1) The weighted average purchase price for the transaction reported was $7.36, and the range of prices were between $7.345 and $7.36, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided. |